Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to -$1.16.

  • Arcutis Biotherapeutics' EPS (Weighted Average and Diluted) rose 118.18% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.35, marking a year-over-year increase of 78.92%. This contributed to the annual value of -$1.16 for FY2024, which is 69.31% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$1.16 for FY2024, which was up 69.31% from -$3.78 recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' EPS (Weighted Average and Diluted) registered a high of -$1.16 during FY2024, and its lowest value of -$5.66 during FY2022.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$3.78 (2023), whereas its average is -$3.53.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 35.41% in 2022, then skyrocketed by 69.31% in 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$3.80 in 2020, then decreased by 10.00% to -$4.18 in 2021, then tumbled by 35.41% to -$5.66 in 2022, then soared by 33.22% to -$3.78 in 2023, then skyrocketed by 69.31% to -$1.16 in 2024.